Chemical Name : Eplerenone
Inspra Information : Inspra contains eplerenone, a blocker of aldosterone binding at the mineralocorticoid receptor. INSPRA is indicated to improve survival of stable patients with left ventricular systolic dysfunction (ejection fraction 40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.
INSPRA tablets contain 25 mg or 50 mg of eplerenone. The principal risk of INSPRA is hyperkalemia. Hyperkalemia can cause serious, sometimes fatal, arrhythmias. This risk can be minimized by patient selection, avoidance of certain concomitant treatments, and monitoring. For patient selection and avoidance of certain
INDICATIONS AND USAGE
Congestive Heart Failure Post-Myocardial Infarction
INSPRA is indicated to improve survival of stable patients with left ventricular systolic
dysfunction (ejection fraction £40%) and clinical evidence of congestive heart failure after an
acute myocardial infarction.
INSPRA is indicated for the treatment of hypertension. INSPRA may be used alone or in
combination with other antihypertensive agents.
Inspra Side Effects : Inspra side effect profile coming soon:
Drug-drug interaction studies were conducted with a 100 mg dose of eplerenone.
Eplerenone is metabolized primarily by CYP3A4. A potent inhibitor of CYP3A4 (ketoconazole)
caused increased exposure of about 5-fold while less potent CYP3A4 inhibitors (erythromycin,
saquinavir, verapamil, and fluconazole) gave approximately 2- fold increases. Grapefruit juice
caused only a small increase (about 25%) in exposure.
The recommended dose of INSPRA is 50 mg once daily. Treatment should be initiated at 25 mg
once daily and titrated to the target dose of 50 mg once daily preferably within 4 weeks as
tolerated by the patient. INSPRA may be administered with or without food.
Serum potassium should be measured before initiating INSPRA therapy, within the first week
and at one month after the start of treatment or dose adjustment. Serum potassium should be
assessed periodically thereafter. Factors such as patient characteristics and serum potassium
levels may indicate that additional monitoring is appropriate.
INSPRA (Eplerenone) binds to the mineralocorticoid receptor and blocks the binding of aldosterone, a
component of the renin-angiotensin-aldosterone-system (RAAS). Aldosterone synthesis, which
occurs primarily in the adrenal gland, is modulated by multiple factors, including angiotensin II
and non-RAAS mediators such as adrenocorticotropic hormone (ACTH) and potassium.
Aldosterone binds to mineralocorticoid receptors in both epithelial (e.g., kidney) and
nonepithelial (e.g., heart, blood vessels, and brain) tissues and increases blood pressure through
induction of sodium reabsorption and possibly other mechanisms.
INSPRA (Eplerenone) has been shown to produce sustained increases in plasma renin and serum
aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on
renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels
do not overcome the effects of INSPRA (Eplerenone).
The generic alternative is not manufatured by the company that makes the brand product.
The content on this page has been supplied to CanDrug.com by an independent third party contracted to provide information for our website. CanDrug relies on these third parties to create and maintain this information and cannot guarantee the medical efficacy, accuracy or reliability of the information that has been provided to us. If you require any advice or information about the drugs on this page, a medical condition or treatment advice, you should always speak to a health professional. Please note that not all products, including any referenced in this page, are shipped by our affiliated Canadian Pharmacy. We affiliate with other dispensaries that ship product to our customers from the following jurisdictions: Canada, Singapore, New Zealand, Turkey, Mauritius, India, and United Kingdom. The items in your order maybe shipped from any of the above jurisdictions. The products are sourced from various countries as well as those listed above. Rest assured, we only affiliate with our authorized dispensaries that procure product through reliable sources.
Back to Main Drug Information Page
In addition to dispensing from our affiliated Canadian dispensing pharmacy, we also dispense your medications from international fulfillment centers that are approved by the regulatory bodies from their respective countries. CanDrug.com dispenses medications from fulfillment centers around the world including and not limited to Canada, Singapore, New Zealand, Turkey, Mauritius, India, and United Kingdom. All prices are in US dollars.